Replimune Group Inc (REPL)

$9.89

-0.17

(-1.69%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $9.79
    $10.17
    $9.89
    downward going graph

    1.01%

    Downside

    Day's Volatility :3.74%

    Upside

    2.75%

    downward going graph
  • $4.92
    $21.63
    $9.89
    downward going graph

    50.25%

    Downside

    52 Weeks Volatility :77.25%

    Upside

    54.28%

    downward going graph

Returns

PeriodReplimune Group IncSector (Health Care)Index (Russel 2000)
3 Months
54.05%
6.4%
0.0%
6 Months
25.99%
6.0%
0.0%
1 Year
-51.8%
9.6%
0.0%
3 Years
-70.04%
14.8%
-19.4%

Highlights

Market Capitalization
617.8M
Book Value
$6.1
Earnings Per Share (EPS)
-3.24
Wall Street Target Price
14.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-25.66%
Return On Equity TTM
-46.42%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-230.2M
Diluted Eps TTM
-3.24
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.27
EPS Estimate Next Year
-3.03
EPS Estimate Current Quarter
-0.79
EPS Estimate Next Quarter
-0.8

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Replimune Group Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
15
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 41.56%

Current $9.89
Target $14.00

Technicals Summary

Sell

Neutral

Buy

Replimune Group Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Replimune Group Inc
Replimune Group Inc
25.67%
25.99%
-51.8%
-70.04%
-19.85%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Replimune Group Inc
Replimune Group Inc
NA
NA
NA
-3.27
-0.46
-0.26
NA
6.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Replimune Group Inc
Replimune Group Inc
Buy
$617.8M
-19.85%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Replimune Group Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 111.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 270.6%

Institutional Holdings

  • Baker Bros Advisors LP

    15.54%
  • T. Rowe Price Associates, Inc.

    10.66%
  • State Street Corporation

    10.56%
  • FCPM III SERVICES BV

    7.92%
  • BlackRock Inc

    7.51%
  • Redmile Group, LLC

    6.07%

Company Information

replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.

Organization
Replimune Group Inc
Employees
331
CEO
Mr. Philip Astley-Sparke F.S.A.
Industry
Health Technology

FAQs